Understanding pharmacokinetics of novel prolonged release dienogest 2 mg / ethinyl-estradiol 0.02 mg oral contraceptive formulation: clinical applications.

Abstract

INTRODUCTION: Combined oral contraceptives (COCs) have traditionally evolved through changes in estrogen and progestin type and dose to improve safety and tolerability. More recently, drug-delivery technology has emerged as an additional strategy to modify pharmacokinetic (PK) profiles without altering hormonal components. AREAS COVERED: A structured search of MEDLINE and regulatory sources was conducted to review the PK and pharmacodynamic characteristics of a prolonged-release COC containing dienogest (DNG) 2 mg and ethinylestradiol (EE) 0.02 mg, and to explore their clinical implications. Compared with immediate-release formulations, prolonged-release DNG/EE produces delayed peak concentrations, lower plasma peak levels, and reduced intra-day hormonal fluctuations while maintaining comparable overall exposure. EXPERT OPINION: Clinical evidence indicates contraceptive efficacy comparable to other COCs, with improved bleeding control compared with an immediate-release formulation. Both the intrinsic endometrial effects of DNG and more stable hormonal exposure may contribute to this finding. The formulation also provides antiandrogenic effects that may benefit hirsutism and acne. The safety profile appears broadly consistent with other low-dose COCs, although the effect on thromboembolic risk remains uncertain. Prolonged-release technology adds a new dimension to contraceptive choice and may facilitate individualized COC selection. Further comparative and post-marketing studies are needed to establish its clinical advantages and long-term safety.

Abstract as supplied by the indexing source. © the authors / publisher.